Amgen (AMGN) is in focus after a packed stretch of product and earnings news, including European approval for Imdelltra in small cell lung cancer and fresh concerns around Tavneos and Prolia that weighed on sentiment.
See our latest analysis for Amgen.
At a share price of $338.22, Amgen has a 1-day share price return of 3.03% and a 30-day share price return of 4.44%, while the 90-day share price return is down 7.99%. This hints at cooling momentum despite a 1-year total shareholder return of 21.38% and a 3-year total shareholder return of 67.62%.
If product news and regulatory shifts around Amgen have your attention, it can be useful to compare with other healthcare opportunities using our screener for 39 healthcare AI stocks
So, with solid Q1 results, fresh oncology approvals, and visible pressure in parts of the portfolio, is Amgen’s current valuation leaving meaningful upside on the table, or is the stock already pricing in most of the future growth story?
Most Popular Narrative: 4% Undervalued
With Amgen last closing at $338.22 against a narrative fair value of about $352, the current set up centers on whether modest growth and high margins can support that gap.
Advancements in personalized and targeted therapies, reflected in the robust late-stage pipeline (e.g., MariTide for obesity/type 2 diabetes, Repatha and olpasiran for cardiovascular, multiple bispecific T-cell engagers for oncology), position Amgen to launch high-margin, first-in-class products that drive both top-line growth and margin expansion in the coming years.
Want to see what sits behind that confidence in high margin launches and earnings power? The key tension is steady growth assumptions paired with a premium future earnings multiple.
Result: Fair Value of $352.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that premium future P/E and fair value gap rest on assumptions that drug pricing pressure and biosimilar competition will not bite harder into key products such as Prolia.
Find out about the key risks to this Amgen narrative.
Next Steps
With sentiment mixed between oncology momentum and pricing risks, this is a moment to look at the numbers yourself and decide quickly where you stand, starting with the balance between 3 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Amgen is on your radar, do not stop there. Broaden your watchlist with other stock ideas that match your style and risk comfort.
- Target potential upside by scanning for 47 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
- Strengthen your income stream by focusing on companies in 10 dividend fortresses that offer higher yields with supporting metrics.
- Prioritize resilience by filtering for 63 resilient stocks with low risk scores that pair lower risk profiles with solid business characteristics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com